Lipocine Inc. announced that its Phase 3 clinical trial data for LPCN 1154, an oral treatment for postpartum depression, will be presented at the 2026 American Society of Clinical Psychopharmacology Annual Meeting. LPCN 1154 is a novel oral neuroactive steroid designed to rapidly stabilize postpartum depression symptoms with improved tolerability and no need for intensive monitoring. This presentation highlights Lipocine's progress in developing a potentially safe, at-home treatment option for postpartum depression. The company continues to advance its pipeline of oral therapies for various conditions.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
